secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-07-23T21:15:56+00:00
Accession:  0001193125-26-314591
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Faeth Therapeutics grants performance options to employees; CEO receives 398,018 shares tied to $70 stock price hurdle
--------------------------------------------------------------------------------

- CEO Anand Parikh granted 398,018 performance-based stock options; exercise price equals grant-date closing price.
- Options vest in a single tranche when 30-day average closing price reaches $70.00 within 4 years, or upon change in control with ≥$70 per share consideration.
- General Counsel Christopher Gerry and SVP Finance Josiah Craver each received options (84,766 and 30,824, respectively); both no longer classified as executive officers as of June 2026.
- If the stock price hurdle is not met within the performance period or upon termination of service, all performance options are forfeited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526314591/0001193125-26-314591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526314591/d68855d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-314591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer